One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...

GLP-1 class of weight loss and diabetes drugs are linked to previously unrecognized health risks and benefits, according to a ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...